TY - JOUR
T1 - Extracorporeal Hyperoxygenation Therapy (EHT) for Carbon Monoxide Poisoning
T2 - In-Vitro Proof of Principle
AU - Steuer, Niklas B.
AU - Schlanstein, Peter C.
AU - Hannig, Anke
AU - Sibirtsev, Stephan
AU - Jupke, Andreas
AU - Schmitz-Rode, Thomas
AU - Kopp, Rüdger
AU - Steinseifer, Ulrich
AU - Wagner, Georg
AU - Arens, Jutta
N1 - Funding Information:
Funding: This project was supported by the Ministerium für Wirtschaft, Innovation, Digitales und Energie des Landes Nordrhein-Westfalen including funds from the European Fund for Regional Development (EFRE), Support Code 1606pv011.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/1
Y1 - 2022/1
N2 - Carbon monoxide (CO) poisoning is the leading cause of poisoning-related deaths globally. The currently available therapy options are normobaric oxygen (NBO) and hyperbaric oxygen (HBO). While NBO lacks in efficacy, HBO is not available in all areas and countries. We present a novel method, extracorporeal hyperoxygenation therapy (EHT), for the treatment of CO poisoning that eliminates the CO by treating blood extracorporeally at elevated oxygen partial pressure. In this study, we proof the principle of the method in vitro using procine blood: Firstly, we investigated the difference in the CO elimination of a hollow fibre membrane oxygenator and a specifically designed batch oxygenator based on the bubble oxygenator principle at elevated pressures (1, 3 bar). Secondly, the batch oxygenator was redesigned and tested for a broader range of pressures (1, 3, 5, 7 bar) and temperatures (23, 30, 37 °C). So far, the shortest measured carboxyhemoglobin half-life in the blood was 21.32 min. In conclusion, EHT has the potential to provide an easily available and effective method for the treatment of CO poisoning. View Full-Text.
AB - Carbon monoxide (CO) poisoning is the leading cause of poisoning-related deaths globally. The currently available therapy options are normobaric oxygen (NBO) and hyperbaric oxygen (HBO). While NBO lacks in efficacy, HBO is not available in all areas and countries. We present a novel method, extracorporeal hyperoxygenation therapy (EHT), for the treatment of CO poisoning that eliminates the CO by treating blood extracorporeally at elevated oxygen partial pressure. In this study, we proof the principle of the method in vitro using procine blood: Firstly, we investigated the difference in the CO elimination of a hollow fibre membrane oxygenator and a specifically designed batch oxygenator based on the bubble oxygenator principle at elevated pressures (1, 3 bar). Secondly, the batch oxygenator was redesigned and tested for a broader range of pressures (1, 3, 5, 7 bar) and temperatures (23, 30, 37 °C). So far, the shortest measured carboxyhemoglobin half-life in the blood was 21.32 min. In conclusion, EHT has the potential to provide an easily available and effective method for the treatment of CO poisoning. View Full-Text.
KW - UT-Hybrid-D
KW - Poisoning
KW - extracorporeal therapy
KW - hyperoxygenation
KW - Oxygenator
KW - hollow fibre membrane oxygenator
KW - bubble oxygenator
KW - Carbon monoxide
UR - https://www.mdpi.com/2077-0375/12/1/56
U2 - 10.3390/membranes12010056
DO - 10.3390/membranes12010056
M3 - Article
SN - 2077-0375
VL - 12
JO - Membranes
JF - Membranes
IS - 1
M1 - 56
ER -